Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France; and Aditi Shastri, MBBS, Albert Einstein College of Medicine, New York City, NY, discuss key takeaways related to acute myeloid leukemia from iwAL 2025. Mechanisms of resistance to azacitidine-venetoclax, strategies for relapse, including novel combinations, and challenges with MCL-1 inhibition were reviewed. Additional topics included targeting leukemic stem cells, menin inhibitors in NPM1-mutated AML, and the need for international collaboration to optimize therapeutic strategies.